Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

眼部炎症中的玻璃体蛋白质组和炎症介质

• 批准号: 7975936
• 负责人: DARBY THOMPSON
• 金额: $ 13.93万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-11-01 至 2011-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7975936
• 关键词: Vitreous; Proteome; Inflammatory; Mediators; Ocular

This study will examine the proteins of people with uveitis, or inflammation of the eyes. Evaluating the vitreous, the colorless transparent substance that fills the eyeball in back of the lens, is now possible with the use of new microtechnology. There is an opportunity to evaluate the kinds of proteins that are present in severe, noninfectious sight-threatening uveitis. Patients ages 18 and older who have been enrolled in the Multicenter Uveitis Steroid Treatment (MUST) study at NIH may be eligible for this study. Up to 200 patients eventually may be enrolled. Researchers will study the vitreous that will be removed from patients' eyes during an operation to insert a steroid implant. The steroid implant is used instead of immunosuppressive therapy, a way to reduce the action of the immune system. Patients will undergo a procedure involving a small hole made in the eye into which the implant is placed. Normally a small amount of the vitreous comes out during that procedure, and in this study, the vitreous specimen will be taken for testing of inflammatory products. At the same time, a small sample of blood, about 1-1/2 tablespoons, will be collected so that the researchers can compare inflammatory products that may be in the blood with those in the vitreous. If a patient needs to have the implant placed again during the study, he or she would be asked permission for collection of the vitreous and blood samples, as previously. Samples collected will not be used to diagnose patients' conditions or to change any treatments being done. All samples will be labeled with special code numbers so that there is no identifying information about patients. This study will not involve examinations or scheduled visits of patients.

这项研究将检查患有葡萄膜炎或眼睛炎症的人的蛋白质。现在，通过使用新的显微技术，可以评估玻璃体（填充眼球晶状体后部的无色透明物质）。有机会评估严重、非感染性威胁视力的葡萄膜炎中存在的蛋白质种类。 已入组 NIH 多中心葡萄膜炎类固醇治疗 (MUST) 研究的 18 岁及以上患者可能有资格参加本研究。最终可能会招募多达 200 名患者。研究人员将研究在植入类固醇植入物的手术中从患者眼睛中取出的玻璃体。使用类固醇植入物代替免疫抑制疗法，这是一种减少免疫系统作用的方法。 患者将接受在眼睛上打一个小孔并植入植入物的手术。通常，在该过程中会产生少量玻璃体，在本研究中，将采集玻璃体样本用于检测炎症产物。同时，将收集少量血液样本（约1-1/2汤匙），以便研究人员能够比较血液中可能存在的炎症产物与玻璃体中的炎症产物。如果患者在研究期间需要再次植入植入物，则将像以前一样征求他或她的同意，以收集玻璃体和血液样本。收集的样本不会用于诊断患者的病情或改变正在进行的任何治疗。所有样本都将贴上特殊代码编号，这样就不存在有关患者的识别信息。这项研究不会涉及患者的检查或定期就诊。